493 related articles for article (PubMed ID: 29592876)
1. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.
DeFilipp Z; Peled JU; Li S; Mahabamunuge J; Dagher Z; Slingerland AE; Del Rio C; Valles B; Kempner ME; Smith M; Brown J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Ballen KK; Sung AD; Dalton TE; Messina JA; Dettmer K; Liebisch G; Oefner P; Taur Y; Pamer EG; Holler E; Mansour MK; van den Brink MRM; Hohmann E; Jenq RR; Chen YB
Blood Adv; 2018 Apr; 2(7):745-753. PubMed ID: 29592876
[TBL] [Abstract][Full Text] [Related]
2. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers.
Goeser F; Sifft B; Stein-Thoeringer C; Farowski F; Strassburg CP; Brossart P; Higgins PG; Scheid C; Wolf D; Holderried TAW; Vehreschild MJGT; Cruz Aguilar MR
Eur J Haematol; 2021 Aug; 107(2):229-245. PubMed ID: 33934412
[TBL] [Abstract][Full Text] [Related]
3. Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract.
DeFilipp Z; Damania AV; Kim HT; Chang CC; El-Jawahri A; McAfee SL; Bottoms AS; Toncheva V; Smith MM; Dolaher M; Perry L; White M; Diana B; Connolly S; Dey BR; Frigault MJ; Newcomb RA; O'Donnell PV; Spitzer TR; Mansour MK; Weber D; Ajami NJ; Hohmann E; Jenq RR; Chen YB
Blood Adv; 2024 May; 8(9):2074-2084. PubMed ID: 38471063
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial.
Zhao Y; Li X; Zhou Y; Gao J; Jiao Y; Zhu B; Wu D; Qi X
Front Immunol; 2021; 12():678476. PubMed ID: 34220825
[TBL] [Abstract][Full Text] [Related]
5. Treatment of intestinal graft-versus-host disease with unrelated donor fecal microbiota transplantation capsules: A case report.
Mao D; Jiang Q; Sun Y; Mao Y; Guo L; Zhang Y; Man M; Ouyang G; Sheng L
Medicine (Baltimore); 2020 Sep; 99(38):e22129. PubMed ID: 32957333
[TBL] [Abstract][Full Text] [Related]
6. Fecal Microbiota Transplantation: Restoring the Injured Microbiome after Allogeneic Hematopoietic Cell Transplantation.
DeFilipp Z; Hohmann E; Jenq RR; Chen YB
Biol Blood Marrow Transplant; 2019 Jan; 25(1):e17-e22. PubMed ID: 30408565
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation].
Zheng YY; Yang XT; Lin GQ; Bian MR; Si YJ; Zhang XX; Zhang YM; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):401-407. PubMed ID: 37550190
[No Abstract] [Full Text] [Related]
8. Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis.
Rashidi A; Ebadi M; Rehman TU; Elhusseini H; Kazadi D; Halaweish H; Khan MH; Hoeschen A; Cao Q; Luo X; Kabage AJ; Lopez S; Ramamoorthy S; Holtan SG; Weisdorf DJ; Khoruts A; Staley C
Cancer Res Commun; 2024 Jun; 4(6):1454-1466. PubMed ID: 38767452
[TBL] [Abstract][Full Text] [Related]
9. Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients.
van Lier YF; Davids M; Haverkate NJE; de Groot PF; Donker ML; Meijer E; Heubel-Moenen FCJI; Nur E; Zeerleder SS; Nieuwdorp M; Blom B; Hazenberg MD
Sci Transl Med; 2020 Aug; 12(556):. PubMed ID: 32801142
[TBL] [Abstract][Full Text] [Related]
10. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
Webb BJ; Brunner A; Ford CD; Gazdik MA; Petersen FB; Hoda D
Transpl Infect Dis; 2016 Aug; 18(4):628-33. PubMed ID: 27214585
[TBL] [Abstract][Full Text] [Related]
11. Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
Rashidi A; Ebadi M; Rehman TU; Elhusseini H; Kazadi D; Halaweish H; Khan MH; Hoeschen A; Cao Q; Luo X; Kabage AJ; Lopez S; Holtan SG; Weisdorf DJ; Khoruts A; Staley C
J Clin Oncol; 2023 Dec; 41(34):5306-5319. PubMed ID: 37235836
[TBL] [Abstract][Full Text] [Related]
12. Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial.
Rashidi A; Ebadi M; Rehman TU; Elhusseini H; Kazadi D; Halaweish H; Khan MH; Hoeschen A; Cao Q; Luo X; Kabage AJ; Lopez S; Holtan SG; Weisdorf DJ; Khoruts A; Staley C
Clin Cancer Res; 2023 Dec; 29(23):4920-4929. PubMed ID: 37787998
[TBL] [Abstract][Full Text] [Related]
13. Profiling the Fungal Microbiome after Fecal Microbiota Transplantation for Graft-versus-Host Disease: Insights from a Phase 1 Interventional Study.
van Lier YF; Rolling T; Armijo GK; Zhai B; Haverkate NJE; Meijer E; Nur E; Blom B; Peled JU; van den Brink MRM; Hohl TM; Hazenberg MD; Markey KA
Transplant Cell Ther; 2023 Jan; 29(1):63.e1-63.e5. PubMed ID: 36280104
[TBL] [Abstract][Full Text] [Related]
14. The impact of intestinal microbiota in antithymocyte globulin-based myeloablative allogeneic hematopoietic cell transplantation.
Gu Z; Xiong Q; Wang L; Wang L; Li F; Hou C; Dou L; Zhu B; Liu D
Cancer; 2022 Apr; 128(7):1402-1410. PubMed ID: 35077579
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease.
van Lier YF; Vos J; Blom B; Hazenberg MD
Gut Microbes; 2023; 15(1):2178805. PubMed ID: 36794370
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
Ramalingam S; Siamakpour-Reihani S; Bohannan L; Ren Y; Sibley A; Sheng J; Ma L; Nixon AB; Lyu J; Parker DC; Bain J; Muehlbauer M; Ilkayeva O; Kraus VB; Huebner JL; Spitzer T; Brown J; Peled JU; van den Brink M; Gomes A; Choi T; Gasparetto C; Horwitz M; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Sung AD
PLoS One; 2021; 16(6):e0252995. PubMed ID: 34170918
[TBL] [Abstract][Full Text] [Related]
17. Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study).
Dougé A; Ravinet A; Corriger A; Cabrespine A; Wasiak M; Pereira B; Sokol H; Nguyen S; Bay JO
BMJ Open; 2023 May; 13(5):e068480. PubMed ID: 37130682
[TBL] [Abstract][Full Text] [Related]
18. [Fecal microbiota transplantation for graft-versus-host disease in children and adults: methods, clinical effects, safety].
Goloshchapov OV; Chukhlovin AB; Bakin EA; Stanevich OV; Klementeva RV; Shcherbakov AA; Shvetsov AN; Suvorova MA; Bondarenko SN; Kucher MA; Kulagin AD; Zubarovskaya LS; Moiseev IS
Ter Arkh; 2020 Sep; 92(7):43-54. PubMed ID: 33346444
[TBL] [Abstract][Full Text] [Related]
19. Fecal Microbiota Transplantation for Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Expanding the Horizon into Pediatrics.
Gray AN; DeFilipp Z
Transplant Cell Ther; 2023 Aug; 29(8):484-491. PubMed ID: 37169290
[TBL] [Abstract][Full Text] [Related]
20. Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature.
Biernat MM; Urbaniak-Kujda D; Dybko J; Kapelko-Słowik K; Prajs I; Wróbel T
J Int Med Res; 2020 Jun; 48(6):300060520925693. PubMed ID: 32527171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
